Butyrate enhancement of interleukin-1β production via activation of oxidative stress pathways in lipopolysaccharide-stimulated THP-1 cells

Hideo Ohira,¹,²* Yoshiro Fujioka,¹ Chikae Katagiri,¹ Mayumi Yano,¹ Rie Mamoto,¹ Michiko Aoyama,² Makoto Usami² and Masamichi Ikeda¹

¹Division of Clinical Nutrition, Faculty of Nutrition, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan
²Division of Nutrition and Metabolism Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan

(Received 13 February, 2011; Accepted 1 April, 2011; Published online 24 August, 2011)

In inflammatory bowel diseases, interleukin-1β production is accelerated. Butyrate, a short chain fatty acid, plays an important role in inflammatory bowel diseases. We investigated the effect of butyrate on interleukin-1β production in macrophage and elucidated its underlying mechanism. We stimulated THP-1 cells, a human premonocytic cell line, by lipopolysaccharide alone and by butyrate with lipopolysaccharide. Butyrate with lipopolysaccharide increased interleukin-1β production more than lipopolysaccharide alone. Butyrate with lipopolysaccharide increased caspase-1 activity more than lipopolysaccharide alone. As for the phosphorylation pathway, PD98059 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor) decreased caspase-1 activity and interleukin-1β production to approximately 50% of the controls. Pertussis toxin (G protein-coupled signal transduction pathway inhibitor) also reduced interleukin-1β production to approximately 50%. Butyrate with lipopolysaccharide increased reactive oxygen species levels more than lipopolysaccharide alone. The addition of N-acetyl L-cysteine reduced reactive oxygen species levels to a level similar to that of lipopolysaccharide alone. Butyrate with lipopolysaccharide increased nitric oxide production more than lipopolysaccharide alone, and the addition of N-acetyl L-cysteine reduced the elevated amount of nitric oxide. In conclusions, butyrate enhances interleukin-1β production by activating caspase-1, via reactive oxygen species, the phosphorylation of MAPK, and G protein mediated pathways in lipopolysaccharide stimulated THP-1 cells.

Key Words: butyrate, macrophage, interleukin-1β (IL-1β), caspase-1, reactive oxygen species (ROS)

I

lflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn’s disease, are characterized by the increased migration of leukocytes into intestinal mucosal lesions, necrosis of epithelial cells, and large amounts of enteric ulceration. At the onset or the active phase in IBD, the production of pro-inflammatory cytokines and chemokines, particularly interleukin (IL)-1β, has been observed in these lesions, as has the activation of caspase-1 in macrophages.¹⁻³

Ohkusa et al.⁴ have successfully induced UC-like intestinal tracts in mice by administering enemas using conditioned media from the obligate anaerobe Fusobacterium varium, isolated from the intestinal mucosa of UC patients. They suggest that short chain fatty acids (SCFAs) generated by Fusobacterium varium, particularly butyrate, played important roles in this induction. Efthimiadi et al.⁵ reported that butyrate enhances IL-1β production from monocytes. These studies suggest that butyrate induced IL-1β may be closely and critically associated with the pathogenesis of the disease. Therefore, we hypothesize that butyrate promotes the inflammation in mucosa by producing IL-1β from activated macrophages.

Although IL-1β is regulated by p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases (ERKs) in human smooth muscle cells,⁶ the mechanism by which butyrate induces IL-1β production in monocyte-macrophages is not yet understood. In the present study, we investigated the effect of butyrate on the expression of IL-1β and caspase-1 activity in THP-1 cells, a human premonocytic cell line, and characterized the signal transduction pathways by which butyrate induces IL-1β production.

Materials and Methods

Materials. Lipopolysaccharide (LPS; Salmonella typhosa 0901) was purchased from Difco (Detroit, MI); PD98059, SB203580, SP600125, and GF109203X from Calbiochem (La Jolla, CA); Diphenyleneiodonium chloride from Sigma Chem. (St. Louis, MO); Ac-YV AD-CHO from BIOMOL (Plymouth, PA); and pertussis toxin (PTX) from Wako Pure Chem. (Osaka, Japan). Oligonucleotide primers were synthesized and purified by BEX (Tokyo, Japan). Total cell protein concentrations were determined using a DC protein assay kit (Bio-Rad Lab., Hercules, CA) with bovine serum albumin (Bio-Rad) as the standard. All other chemicals and materials (except those described below) were obtained from Nacalai Tesque (Kyoto, Japan).

Cells. THP-1 cells (ATCC, Manassas, VA) were cultured in RPMI 1640 or HAM’s F12 medium (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan) with 292 μg/ml L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum (FBS) at 37°C and under 5% CO₂. Differentiation to macrophages was induced with 100 nmol/l phorbol 12-myristate 13-acetate (PMA, Sigma) for 48 h.⁷ Cell viability was examined using an MTT cell viability assay kit (R&D Systems, Minneapolis, MN). The value for cell viability of the positive control cells, which were treated with 0.1 μg/ml LPS with or without 1 nmol/l butyrate in 0.5% dimethylsulfoxide (DMSO, v/v), were standardized as 100%. Incubation medium with or without substrates in all experiments did not significantly affect cell viability (data not shown).

*To whom correspondence should be addressed.
E-mail: oohira@nutr.kobegakuin.ac.jp

©2012 JCBN

doi: 10.3164/jcbn.11-22

J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 59–66
Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from THP-1 cells (5.0×10⁶) using TRizol reagent (Invitrogen, Carlsbad, CA). Single-strand cDNA was synthesized from 1 μg of total RNA using an RT-PCR reverse transcription kit (Maxim Biotech, San Francisco, CA). Incubation was carried out at 37°C for 60 min. The temperature of the reaction was then raised to 94°C for 5 min in order to make the enzyme inactive and was then reduced to 4°C. PCR amplification was performed using a Gene Amp PCR System 9700 (Applied Biosystems, Carlsbad, CA). For semi-quantitative analysis, the linearity of amplification of IL-1β and GAPDH cDNA, depending on the PCR cycle number, was established in preliminary experiments. A total of 30 cycles for IL-1β and GAPDH were performed. Products were analyzed by Kodak 1-D Image Analysis software (Eastman Kodak Co. Ltd., NY). The GAPDH primers used were 5′-CCACCATGGCAAAATCAGTGGA-3′ and 5′-TCTGACGGCAGGTCCAGTCACC-3′. These were designed to yield a 696-bp product. The IL-1β primers used were 5′-AAACAGATGAAGTGCTCCTTCCA-3′ and 5′-GAGAACACCATTTGTTGCTCCA-3′. These were designed to yield a 389-bp product.

IL-1β protein production. THP-1 cells were seeded onto a 24-well plate at density of 1.0×10⁶ cells/well in RPMI 1640 medium with 292 μg/ml L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% FBS and cultured at 37°C for 48 h under a humidified atmosphere of 5% CO₂. After differentiation with 100 nmol/l PMA, cells were washed with PBS and treated with PBS or 0.1 μg/ml LPS alone, 1 mmol/l butyrate with 0.1 μg/ml LPS for 3, 6, 12, and 24 h.(8) The control cells were treated only with phosphate buffered saline (PBS), and positive control cells were treated with LPS alone. IL-1β protein concentration in the medium was examined by IL-1β Human ELISA Kit (R&D Systems). The optical density for each specimen were determined at λ₆₅₀ 450 nm, λₑₐ 550 nm using a Molecular Devices microplate reader (Wako).

Caspase-1 activity. Caspase-1 activity was determined using a caspase-1 fluorometric assay kit (R&D Systems). Cells treated with or without chemicals for 6 h were washed in cold PBS at 3 times, then re-suspended in 400 μl of cold lysis buffer and incubated on ice for 10 min. The cell lysates were pelleted, followed by transfer of the supernatants to microcentrifuge tubes. 50 μl of 2× reaction buffer with 1 M dithiothreitol (DTT) and 5 μl of Caspase-1 fluorogenic substrate (WEHD-AFC) were added to each well, followed by 37°C for 2 h incubation. A control reaction of treated cells without WEHD-AFC was incubated. The fluorometrical density for each specimen were determined at λₑₐ 400 nm, λₑₐ 505 nm using a GENios microplate reader (Wako). The results are expressed as fold increase, with caspase-1 activity seen in 0.5% DMSO treated cells (the vehicle control) standardized as 1-fold.

Western blotting. For Western blot analysis, 5×10⁶ cells were lysed in M-PER Mammalian Protein Extraction reagent (Pierce, Rockford, IL). Denature proteins were separated using SDS-polyacrylamide gel electrophoresis on a 10 or 15% polyacrylamide gel and then transferred onto Immobilon-P membranes (Millipore, Billerica, MA).(9) We used rabbit anti-human phospho-p38 MAPK, rabbit anti-human p38 MAPK, rabbit anti-human phospho-extracellular signal-regulated kinase1/2 (ERK1/2), rabbit anti-human ERK1/2, rabbit anti-human phospho-c-Jun N-terminal kinase1/2 (JNK1/2), rabbit anti-human JNK1/2, rabbit anti-human phospho-mitogen-activated protein kinase1/2 (MEK1/2), rabbit anti-human MEK1/2 (R&D Systems, Minneapolis, MN), rabbit anti-human Caspase-1 (BIOMOL International), rabbit anti-human actin (Santa Cruz Biotechnology, Santa Cruz, CA), anti-rabbit antibody horseradish peroxidase-linked immunoglobulin G (IgG) antibodies (GE Healthcare, Bucks, UK), or non-labeled rabbit IgG antibodies (Wako Pure Chem.,). The blots were developed using an ECL (GE Healthcare) and the images were then analysed by Kodak 1-D Image Analysis software. The ratios of protein expression levels of protein were determined by dividing the band intensity of the product of interest by that of the corresponding actin band.

Effects of specific inhibitors. Differentiated cells were treated with 0.5% (v/v) DMSO alone (vehicle), 1 mmol/l butyrate with 0.1 μg/ml LPS, or 1 mmol/l butyrate with 0.1 μg/ml LPS in 50 mmol/l of PD98059 (PD), 50 mmol/l of SB203580 (SB), 10 mmol/l of SP600125 (SP), 10 mmol/l of GF109203X (GF), 10 mmol/l of diphenyleneiodonium (DPI), 20 mmol/l of N-acetyl...
L-cysteine (NAC), or 100 mmol/l of Ac-YVAD-CHO (YVAD), which were dissolved in DMSO.\(^8,9\) The positive control cells were treated with 0.1 μg/ml LPS alone for 6 h (caspase-1 assay) or 24 h (IL-1β assay).

**Effects of PTX.** THP-1 cells were treated with 100 ng/ml PTX at 37°C for 60 min. They were then treated with 0.1 μg/ml LPS alone or 1 mmol/l butyrate with LPS in RPMI 1640 medium for 24 h.

**Detection of reactive oxygen species products.** The intracellular production of reactive oxygen species (ROS) was assessed using a 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate fluorescence probe (carboxy-H\(_2\)DCF-DA, Invitrogen, Carlsbad, CA).\(^9\) THP-1 cells were treated with 0.1 mg/ml LPS for 60 min with or without 1 mmol/l butyrate, or with or without 20 mmol/l NAC for 60 min. Then, cells were exposed to 10 mmol/l carboxy-H\(_2\)DCFDA in 1 ml PBS for 30 min at 37°C. Cells were washed twice, re-suspended in 1 ml PBS, and analyzed by fluorescence on a FACSCanto (Becton Dickson, Mountain View, CA). The intensity of DCF in the cells was analyzed by WinMDI ver 2.8 software (http://facs.scripps.edu/software.html).

**Nitrite/nitrate quantification.** THP-1 cells were seeded onto a 24-well plate at density of 1.0 \(\times\) 10\(^6\) cells/well in HAM’s F12 medium. Differentiation cells were treated with 0.5 μg/ml LPS alone or 1 mM butyrate with LPS, and vehicle (0.5% DMSO, v/v) alone, butyrate with LPS and 20 mM NAC, and LPS with NAC for 6, 12, 24 h in HAM’s F12 medium. Nitric oxide (NO) production from incubate medium was determined by measuring the amount of nitrite/nitrate (NO\(_2^-\)/NO\(_3^-\)), a stable oxidation end product of NO, NO\(_2^-\)/NO\(_3^-\) Assay Kit-C2 (DOJINDO Lab., Kumamoto, Japan). The optical density for each specimen were determined at 540 nm using a Molecular Devices microplate reader (Wako).
Protein determination. Total protein concentrations in lysed THP-1 cells were determined using a DC Protein Assay kit (Bio-Rad Lab.), according to the protocol of the manufacturer, with bovine serum albumin (Bio-Rad Lab.) employed as the standard.

Statistical analysis. Data are expressed as the mean ± SD. Date were assessed by Kruskall-Wallis variance analysis and Dunnet’s multiple comparison test or the Mann-Whitney U test. Statistical analysis was performed by GraphPad Prism ver 4.0 (GraphPad Software Inc., San Diego, CA). Two-tailed values of $p<0.05$ were considered to indicate statistical significance.

Results

Butyrate with LPS increases expression of IL-1β mRNA and protein production. Preliminary experiments using >2 mmol/l butyrate induced excessive toxicity and apoptosis after 24 h (data not shown). A 1 mmol/l butyrate concentration was therefore used in all subsequent experiments. The expression of IL-1β mRNA was not clearly observed in either the controls or the butyrate alone-treated cells. Both LPS alone and butyrate with LPS stimulations elevated the expression of IL-1β mRNA levels (Fig. 1). After 24 h, IL-1β mRNA levels in both stimulations remained elevated to a similar level (data not shown).

LPS alone increased IL-1β protein production in a time-dependent manner compared to those in the controls or in butyrate alone-treated cells. Butyrate with LPS significantly increased IL-1β protein production compared to those in LPS alone-treated cells (Fig. 2).

Butyrate with LPS enhances caspase-1 expression. Next, we determined the caspase-1 protein expression. There was no difference of caspase-1 expression in the controls or the butyrate alone-treated cells. LPS alone significantly increased caspase-1 expression: more than 3-fold above the controls. Butyrate with LPS also increased caspase-1 expression to a similar level, which seems to match an earlier trend compared to LPS alone (Fig. 3 (a) and (b)). These results suggested that IL-1β production in THP-1 cells by LPS alone or butyrate with LPS was mediated by caspase-1 activation.

Effect of kinase inhibitors and antioxidants on caspase-1 activity and IL-1β expression. First, to determine whether butyrate affects the early activation of the MAPKs pathways to induce IL-1β release, we examined phosphorylation of p38 MAPK, c-Jun NH2-terminal kinase1/2 (JNK1/2), mitogen-activated protein kinase kinase1/2 (MEK1/2), and extracellular signal-regulated kinase1/2 (ERK1/2) was analyzed by Western blotting as described in Materials and Methods. Actin was used as the internal control. The pictures are representative results from three independent experiments.
H. Ohira et al.

Fig. 5. Effects of kinase inhibitors and an antioxidant on caspase-1 activity and interleukin-1β (IL-1β) in THP-1 cells treated with butyrate and lipopolysaccharide (LPS). After differentiation, cells were seeded onto a 60-mm dish (caspase-1) or a 24-well plate (IL-1β) at a density of 1 × 10⁶ cells/well and 5 × 10⁵ cells/dish, respectively, in RPMI 1640 medium. After washing, the cells were treated with the vehicle (0.5% v/v dimethylsulfoxide (DMSO)), 100 mmol/l Ac-YVAD-CHO (YVAD), 50 mmol/l PD98059 (PD), 50 mmol/l SB203580 (SB), 10 mmol/l SP600125 (SP), 20 mmol/l N-acetyl L-cysteine (NAC), 10 mmol/l diphenyleneiodonium (DPI), and 10 mmol/l GF109203X (GF). Additional inhibitors or antioxidants cells were incubated at 37°C for 20 min, and then were treated with 0.1 μg/ml LPS alone or 1 mmol/l butyrate with 0.1 μg/ml LPS for 24 h. (a) shows the caspase-1 activity by fluorometric assay. The values in five independent experiments are expressed as fold increase (the mean ± SD) relative to that of the controls. (b) shows IL-1β concentrations measured by ELISA kit. The values in five independent experiments are expressed as the mean ± SD. *p<0.05 vs LPS alone. **p<0.01, ***p<0.001 vs butyrate with LPS, by Kruskall-Wallis variance analysis and Dunnet's multiple comparison test.

Fig. 6. Effects of pertussis toxin (PTX) on interleukin-1β (IL-1β) production in THP-1 cells. Cells were seeded onto a 24-well plate at a density of 1 × 10⁶ cells/well, and then cultured at 37°C for 24 h under a humidified atmosphere of 5% CO₂. After differentiation, cells were treated with the 100 ng/ml PTX, and incubating at 37°C for 1 h. They were then treated with 0.1 μg/ml lipopolysaccharide (LPS) alone or 1 mmol/l butyrate with 0.1 μg/ml LPS for 24 h. IL-1β protein concentrations in the medium were examined by ELISA kit. The values in five independent experiments are expressed as the mean ± SD. Statistical analysis was performed using the Mann-Whitney U test. **p<0.01, vs without PTX treatment.

Fig. 7. Effects of butyrate and N-acetyl L-cysteine (NAC) on reactive oxygen species (ROS) production in THP-1 cells. After differentiation, cells were incubated with 0.1 μg/ml lipopolysaccharide (LPS) alone or 1 mmol/l butyrate with 0.1 μg/ml LPS, or 1 mmol/l butyrate with 0.1 μg/ml LPS and 20 mmol/l NAC, for 1 h. Then, cells were stained with carboxy-H2DCFDA for 30 min. The amount of ROS was determined by FACS analysis. (a) shows the effect of LPS alone and LPS with butyrate. (b) shows the effects of butyrate with LPS, and butyrate with LPS and NAC. Each result is a representative one from three independent experiments.

Butyrate with LPS enhances nitrite/nitrate production via ROS generation. Next, to determine influence of butyrate on ROS production, we used flow cytometry to measure intracellular ROS in THP-1 cells treated with LPS alone and butyrate with LPS. As shown in Fig. 7(a), the control cells exhibited constitutive basal levels of ROS, and the LPS increased these. Butyrate with LPS increased ROS levels to an even greater extent. The addition of NAC, however, reduced ROS levels to a level similar to that seen in LPS alone-treated cells (Fig. 7(b)). We also examined the effects of nitrite/nitrate production. Butyrate with LPS significantly increased nitrite/nitrate production compared to LPS alone (Fig. 8). The addition of NAC resulted in a significant reduction in the elevated amount of nitrite/nitrate by butyrate with LPS.
1,4,5-trisphosphate, increases intracellular Ca$^{2+}$ and 
and 43 increased the intracellular Ca$^{2+}$ in blood mononuclear cells. They showed that stimulation of GPR41 
the association of Gi protein, although we did not examine the 
phosphorylation pathways involving MAP kinase, and G$\text{i}$ protein- 
kinases, well understood, signal pathways involving non-receptor tyrosine 
phenomenon. It has been shown that GPR41 receptors are coupled 
and activate MAPKs promote caspase-1 and IL-1$\beta$ 
expression.$^{17}$ Our results seem to be consistent with these reports. 
Therefore, we postulated that butyrate may lead to accelerated 
NADPH oxidase activity resulting in increased activation of p38 
MAPK, JNK 1/2, MEK1/2, and ERK1/2 pathways, the activation 
of caspase-1, and finally more mature efficient IL-1$\beta$ production. 
However, there is also a possibility that ROS may directly activate 
caspase-1 through a redox-sensitive cysteine residue.$^{18}$ Because 
p38 MAPK, JNK, MEK inhibitors are not fully effective and 
because an increase in caspase-1 expression was observed earlier in 
the butyrate-treated cells than in cells given LPS alone, it 
appears that partial intervention of the direct path needs to be 
considered.

SCFAs such as acetate, propionate, and butyrate are produced 
by anaerobic bacterial fermentation of undigested carbohydrates 
in the colon,$^{19}$ and they are rapidly absorbed to provide energy for 
the colorectal epithelium by means of increased blood flow in 
rectal mucosa.$^{20}$ SCFAs also induce apoptosis in a number of 
colorectal tumor cell lines.$^{21}$ On the other hand, butyrate has anti-
inflammatory effects in the colon,$^{22}$ and it also has a prominent 
immunity regulation effect by modulating IL-8$^{23}$ and macrophage 
inflammatory protein 2 (MIP-2) activities$^{24}$ and suppressing the 
NF-κB activity,$^{25,26}$ leading to the regulation of inflammatory 
cytokines such as TNF-α, IL-6, IL-8, and others.$^{27,28}$

However, the results of a controlled clinical trial that used 
enemas containing sodium butyrate showed that butyrate was not 
effective in the treatment of UC.$^{29,30}$ Suggesting that butyrate’s 
immune control mechanisms use pathways that may lead to both 
suppression and aggravation. As shown in this study, butyrate may 
have a significant influence on the production of IL-1$\beta$. Our data 
can be applied to strategies for preventing anaerobic bacteria from 
producing butyrate, which may be an effective treatment of IBD. 
Pharmacological inhibition of p38 MAPK, JNK 1/2, MEK1/2, 
and ERK1/2 seems to be beneficial effects for the treatment of 
inflammatory responses based on experiments with animal 
models.$^{11,32}$ and IL-1$\beta$ has been reduced by the inhibition of p38 
MAPK phosphorylation in the rat dentate gyrus in vitro.$^{33}$

This study has some limitations. For example, we found that 

--

**Discussion**

In this study, we demonstrated that LPS induced IL-1$\beta$ production 
in THP-1 cells and that butyrate enhanced this production. Butyrate also enhanced caspase-1 activation, ROS production, the 
phosphorylation pathways involving MAP kinase, and G$\text{i}$ protein- 
mediated signaling. The PKC inhibitor used in this study did not 
show any effects. These results seem to demonstrate that butyrate 
Enhances IL-1$\beta$ production by activating caspase-1 via ROS and 
the phosphorylation of MAPK pathways and the Gi protein- 
mediated pathways. 

G protein-coupled receptors (GPCRs) constitute one type of receptor 
localized in the cell membrane, and are also known as 
seven trans-membrane domain receptors. In recent years, it has 
been reported that two GPCRs (GPR41 and GPR43) have an 
affinity for SCFAs.$^{10–13}$

Le Poul et al.$^{11}$ reported that GPR41 and 43 bound to a short-
chain fatty acid acts as a chemo-attractant signal for peripheral 
blood mononuclear cells. They showed that stimulation of GPR41 
and 43 increased the intracellular Ca$^{2+}$ level by SCFA and that 
PTX abolished the response of GPR41 but not of GPR43. Although details regarding the GPCR signal cascade are still not 
well understood, signal pathways involving non-receptor tyrosine 
kinas.$^{12}$ such as phosphatidylinositol 3-kinase (PI3K)$^{13}$ and 
protein kinase C (PKC).$^{14}$ may play a significant role in immune 
reactions. It has been shown that GPR41 receptors are coupled 
with G$\text{i}_0$ and that their activation induces the formation of inositol 
1,4,5-trisphosphate, increases intracellular Ca$^{2+}$ concentration and 
ERK1/2 activation, and decreases intracellular cyclic adenosine 
monophosphate (cAMP).$^{15}$ In this study, we were able to identify 
the association of G$\text{i}$ protein, although we did not examine the 
direct association of GPR41 in IL-1$\beta$ production by butyrate. In 
the future, we aim to clarify the detailed mechanisms involved in 
GPR41 in IL-1$\beta$ production by butyrate. 

NADPH oxidase is the primary enzyme for ROS generation in phagocytic cells.$^{16}$ Excessive ROS stimulate MAPK pathway 
activation$^{39}$ and activate MAPKs promote caspase-1 and IL-1$\beta$ 

Fig. 8. Effects of butyrate and N-acetyl L-cysteine (NAC) on nitric oxide (NO) production in THP-1 cells. After differentiation, cells were treated 
with 0.5% v/v dimethylsulfoxide; DMSO (the controls, closed circle), 1 mmol/l butyrate (open square), 0.5 μg/ml lipopolysaccharide; LPS alone (open 
circle), 1 mmol/l butyrate with 0.5 μg/ml LPS (open triangle), 0.5 μg/ml LPS with 20 mmol/l NAC (closed square), or 1 mmol/l butyrate with 0.5 μg/ml LPS 
and 20 mmol/l NAC (closed triangle) for 6, 12, and 24 h. NO production from THP-1 cells was determined by measuring the amount of nitrite/nitrate 
as described in Materials and Methods. The values from five independent experiments are expressed as the mean ± SD. *p<0.05 vs LPS alone, 
**p<0.01 vs LPS with butyrate, by Kruskall-Wallis variance analysis and Dunnet’s multiple comparison test.

©2012 JCBN
butyrate-mediated induction of activated p38 MAPK occurred within 10 min, nitrite detection outside the cell occurred after 6 h, and intracellular detection of ROS occurred after 60 min. These time lags may be due to the reaction time for NO detection in the medium and the reagent sensitivity of the DCFH-DA fluorescent probe for intracellular ROS detection. Moreover, the LPS concentration (0.1 μg/ml) used to alter NO production in the culture medium was below the lower detection limit. A higher concentration (0.5 μg/ml) should be used to examine these problems.

In conclusion, butyrate enhances IL-1β production by activating caspase-1 via ROS and the phosphorylation of MAPK pathways and the Gi protein mediated pathway in LPS stimulated THP-1 cells.

**Acknowledgments**

This study was supported by Grant-in-Aid for Health-Science Research of Kobe Gakuin University.

**Abbreviations**

- carboxy-H2DCF-DA
- 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate
- DMSO Dimethylsulfoxide
- DPI Diphenyleneiodonium
- ERKs Extracellular signal-regulated kinases

**References**

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. *World J Gastroenterol* 2006; 12: 4807–4812.
2. Dionne S, Hiscott J, D’Agata I, Duhaime A, Seidman EG. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. *Dig Dis Sci* 1997; 42: 1557–1566.
3. McNally ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta in the colonic mucosa of patients with ulcerative colitis. *J Cell Biochem* 1998; 68: 214–219.
4. Okhussa T, Okayasu I, Ohgaihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. *Gut* 2003; 52: 79–83.
5. Eftimiadi C, Stashenko P, Tonetti M, et al. Divergent effect of the anaerobic bacteria by-product butyric acid on the immune response: suppression of T-lymphocyte proliferation and stimulation of interleukin-1 beta production. *Oral Microbiol Immunol* 1991; 6: 17–23.
6. Jung YD, Liu W, Reinmuth N, et al. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. *Angiogenesis* 2001; 4: 155–162.
7. Fujisaki Y, Cooper AD, Fong LG. Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. *J Lipid Res* 1998; 39: 2339–2349.
8. Okumura T, Fujisaki Y, Morimoto S, et al. Chylomicron remnants stimulate release of interleukin-1beta by THP-1 cells. *J Atheroscler Thromb* 2006; 13: 38–45.
9. Kamemura K, Fujisaki Y, Takaishi H, et al. Chylomicron remnants upregulate CD40 expression via the ERK pathway and a redox-sensitive mechanism in THP-1 cells. *Atherosclerosis* 2006; 187: 257–264.
10. Hirasa A, Hara T, Katsumata S, Adachi T, Tsujimoto G. Free fatty acid receptors and drug discovery. *Biol Pharm Bull* 2008; 31: 1847–1851.
11. Le Pou L, Leison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem* 2003; 278: 25481–25489.
12. Sanborn BM, Ku CY, Silykov S, Babich L. Molecular signaling through G-protein-coupled receptors and the control of intracellular calcium in myometrium. *J Soc Gynecol Investig* 2005; 12: 479–487.
13. Radef-Huang J, Seasoltz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. *J Cell Biochem* 2004; 92: 949–966.
14. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. *Oncogene* 2004; 23: 7906–7909.
15. Park JB. Phagocytosis induces superoxide formation and apoptosis in macrophages. *Exp Mol Med* 2003; 35: 325–335.
16. Forman HJ, Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. *Am J Respir Crit Care Med* 2002; 166: S4–S8.
17. Fubini B, Hubbard AR. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in Inflammation and fibrosis. *Free Radic Biol Med* 2003; 34: 1507–1516.
18. Miller DK, Myerson J, Becker JW. The interleukin-1 beta converting enzyme family of cysteine proteases. *J Cell Biochem* 1997; 64: 2–10.
19. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* 2001; 81: 1031–1064.
20. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut* 1987; 28: 1221–1227.
21. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. *Cancer Res* 1994; 54: 3288–3293.
22. Andoh A, Tsujikawa T, Fujiyama Y. Role of dietary fiber and short-chain fatty acids in the colon. *Current Pharm Design* 2003; 9: 347–358.
23. Gibson P, Rosella O. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. *Gut* 1995; 37: 536–543.
24. Ohno Y, Lee J, Fusunyan RD, MacDermott RP, Sanderson IR. Macrophage inflammatory protein-2: chromosomal regulation in rat small intestinal epithelial cells. *Proc Natl Acad Sci USA* 1997; 94: 10279–10284.
25. Segain JP, Rainegeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NF-kappa B inhibition: implications for Crohn’s disease. *Gut* 2000; 47: 397–403.
26. Park JS, Lee EJ, Lee JC, Kim WK, Kim HS. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappa B and ERK signaling pathways. *Int Immunopharmacol* 2007; 7: 70–77.
27. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. *J Biol Chem* 2001; 276: 44641–44646.
28. Lührs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of
inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. *Int J Colorectal Dis* 2001; 16: 195–201.

29 Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. *Aliment Pharmacol Ther* 1996; 10: 729–736.

30 Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. *Gut* 1997; 40: 485–491.

31 ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB203580 in experimental colitis. *Gut* 2002; 50: 507–512.

32 Jaffee BD, Manos EJ, Collins RJ, et al. Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo. *Biochem Biophys Res Commun* 2000; 268: 647–651.

33 Coogan AN, O’Neill LA, O’Connor JJ. The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1 beta on long-term potentiation in the rat dentate gyrus in vitro. *Neuroscience* 1999; 93: 57–69.